STOCK TITAN
  1. Home
  2. News
  3. PDSB

PDS Biotechnology Corporation - PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and infectious diseases. The company's proprietary Versamune® platform leverages synthetic and biodegradable lipids to form nanoparticles that are readily taken up by the immune system. These nanoparticles are designed to activate and direct the immune system to target and eliminate disease-causing cells.

PDS Biotech's lead product candidates include PDS0101, targeting HPV-related cancers, and PDS01ADC, an IL-12 fused antibody drug conjugate. These candidates are part of the company's broader strategy to treat a range of cancers, including head and neck, prostate, breast, cervical, and anal cancers.

Recent achievements include the completion of a Phase 1 clinical trial for PDS0101 and ongoing Phase 2 trials demonstrating positive survival results and tumor shrinkage. The company is preparing to initiate a pivotal clinical trial in advanced head and neck cancers in 2024.

Financially, PDS Biotech reported a net loss of $10.8 million for Q3 2023, primarily due to increased R&D and administrative expenses. Despite this, the company remains focused on advancing its pipeline and has several key partnerships to support its research and development efforts.

News

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announces the appointment of Lars Boesgaard as Chief Financial Officer, effective December 4, 2023. Boesgaard brings over 25 years of healthcare experience and has previously served as CFO of AM-Pharma B.V. and Columbia Care. He holds a Bachelor of Science in Business Administration from the Copenhagen Business School and a Master of Business Administration from the Richard Ivey School of Business, Western University, Ontario, Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
management
-
News

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced positive results from multiple clinical trials, including a 75% survival rate at 36 months in the NCI-led Phase 2 combination trial for advanced HPV16-positive cancer patients, and a 74% 2-year overall survival rate in the VERSATILE-002 Phase 2 trial for HPV16-positive head and neck cancer patients. The company also reported promising interim safety and immune response data for a Phase 1/2 clinical trial for metastatic prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
earnings
-
News

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301, and an investigational immune checkpoint inhibitor (ICI) in advanced cancer patients with HPV16-positive cancers. The trial showed 75% of ICI naïve patients remaining alive at 36 months, with a 12-month survival rate of 72% in ICI resistant patients. PDS0101 plus high doses of ICI and PDS0301 achieved an overall response rate of 63%, while the ORR for PDS0101 plus low doses of ICI and/or PDS0301 was 5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
clinical trial
News

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) will release its financial results for the third quarter of 2023 on November 14, 2023, before the market opens. A conference call will follow to review the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
earnings
-
News

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Rhea-AI Summary
PDS Biotechnology announces immune response data from a Phase 2 clinical trial of PDS0101 in combination with KEYTRUDA in HPV-positive head and neck cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
News

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Rhea-AI Summary
PDS Biotech announces positive interim data for Phase 1/2 clinical trial evaluating PDS0301 in combination with docetaxel for metastatic prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
clinical trial
News

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

Rhea-AI Summary
PDS Biotech announces interim data from VERSATILE-002 trial for head and neck cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.47%
Tags
none
-
News

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Rhea-AI Summary
PDS Biotech announces data demonstrating rapid decline in HPV circulating cell-free DNA (cfHPV-DNA) with lead candidate PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) in cervical cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
none
-
News

PDS Biotech to Present at the LD Micro Main Event XVI

Rhea-AI Summary
PDS Biotech CEO to present at LD Micro Main Event XVI on October 4, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
News

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

Rhea-AI Summary
PDS Biotech reschedules Key Opinion Leader Roundtable on addressing treatments for HPV-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none

FAQ

What is the current stock price of PDS Biotechnology Corporation (PDSB)?

The current stock price of PDS Biotechnology Corporation (PDSB) is $1.65 as of December 20, 2024.

What is the market cap of PDS Biotechnology Corporation (PDSB)?

The market cap of PDS Biotechnology Corporation (PDSB) is approximately 65.8M.

What is PDS Biotechnology Corporation's main area of focus?

PDS Biotechnology focuses on developing next-generation immunotherapies for cancer and infectious diseases using its proprietary Versamune® platform.

What is the Versamune® platform?

The Versamune® platform uses synthetic and biodegradable lipids to form nanoparticles that activate and direct the immune system to target disease-causing cells.

Which cancers are targeted by PDS Biotechnology's therapies?

PDS Biotechnology's therapies target various cancers including head and neck, prostate, breast, cervical, and anal cancers.

What are the recent achievements of PDS Biotechnology?

Recent achievements include completing a Phase 1 clinical trial for PDS0101 and ongoing successful Phase 2 trials showing positive results.

How did PDS Biotechnology perform financially in Q3 2023?

PDS Biotechnology reported a net loss of $10.8 million for Q3 2023, mainly due to higher research and development and administrative expenses.

What is PDS01ADC?

PDS01ADC is an IL-12 fused antibody drug conjugate in development for use in PDS Biotechnology's cancer immunotherapy treatments.

What upcoming events should investors watch?

Investors should watch for the pivotal clinical trial in advanced head and neck cancers planned for 2024.

What are the unique features of PDS Biotechnology's vaccines?

PDS Biotechnology's vaccines induce robust neutralizing antibodies and powerful T-cell responses, including long-lasting memory T-cells.

Where can investors find more information about PDS Biotechnology?

Investors can find more information on the company's official website at www.pdsbiotech.com.

How can the media contact PDS Biotechnology?

Media can contact PDS Biotechnology through Gina Mangiaracina at 6 Degrees via phone at +1 (917) 797-7904 or email at gmangiaracina@6degreespr.com.

Stock PDSB logo
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

#4711 Ranked by Market Cap
N/A Ranked by Dividends

PDSB Stock Data

65.84M
36.02M
3.99%
12.36%
12.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON